Actively Recruiting
A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
Led by Akeso · Updated on 2026-04-23
610
Participants Needed
1
Research Sites
835 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.
CONDITIONS
Official Title
A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to understand and voluntarily sign a written informed consent form before study procedures
- Prior participation in sponsor-initiated clinical trials of Cadonilimab (AK104) with completion of the original trial
- Agreement to participate in extended follow-up procedures
- Willingness to participate in this observational, non-interventional study while possibly joining other clinical studies simultaneously
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University Cancer Hospital
Beijing, China
Actively Recruiting
Research Team
Z
Zhifang Yao，MD
CONTACT
J
Jiafu Ji, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here